Ionis Pharmaceuticals, Inc.

IONS

$74.58

Name : Ionis Pharmaceuticals, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $12,325,281,792.00

EPSttm : -2.04

Ionis Pharmaceuticals, Inc.

$74.58

1.41%

$1.04

IONS — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

9.93

Margin Of Safety %

Put/Call OI Ratio

0.67

EPS Next Q Diff

-0.51

EPS Last/This Y

-0.18

EPS This/Next Y

1.94

Price

74.55

Target Price

105.23

Analyst Recom

1.37

Performance Q

-1.43

Upside

-198.6%

Beta

0.38

Ticker: IONS

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-05-11	IONS	75.43	0.67	0.18	50493
2026-05-12	IONS	75.68	0.67	0.14	50407
2026-05-13	IONS	77.56	0.67	0.00	50470
2026-05-14	IONS	75.68	0.67	0.03	50677
2026-05-15	IONS	74.24	0.66	0.04	50968
2026-05-18	IONS	72.53	0.64	0.59	49673
2026-05-19	IONS	73.83	0.65	0.03	49714
2026-05-20	IONS	75.04	0.64	0.39	49802
2026-05-21	IONS	75.78	0.64	0.19	49839
2026-05-22	IONS	75.6	0.64	0.15	49896
2026-05-26	IONS	76.09	0.64	0.01	49918
2026-05-27	IONS	76.5	0.63	0.27	50524
2026-05-28	IONS	77.29	0.63	0.12	50555
2026-05-29	IONS	76.49	0.63	0.06	50735
2026-06-02	IONS	72.96	0.62	3.69	51022
2026-06-03	IONS	73.78	0.67	0.55	53017
2026-06-04	IONS	75.1	0.67	0.07	53612
2026-06-05	IONS	74.48	0.66	0.81	53756
2026-06-08	IONS	73.55	0.67	0.10	55909
2026-06-09	IONS	74.55	0.67	0.13	56039
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-05-11	IONS	75.40	-203.3	-379.9	-2.56
2026-05-12	IONS	75.81	-203.3	-385.9	-2.56
2026-05-13	IONS	77.61	-203.3	-396.9	-2.56
2026-05-14	IONS	75.69	-203.3	-367.2	-2.56
2026-05-15	IONS	74.20	-203.3	-370.3	-2.56
2026-05-18	IONS	72.52	-203.3	-368.1	-2.56
2026-05-19	IONS	73.83	-203.3	-393.5	-2.56
2026-05-20	IONS	75.05	-203.3	-392.5	-2.56
2026-05-21	IONS	75.78	-203.3	-388.3	-2.56
2026-05-22	IONS	75.56	-203.3	-380.6	-2.56
2026-05-26	IONS	76.07	-203.3	-386.6	-2.56
2026-05-27	IONS	76.46	-203.3	-385.5	-2.56
2026-05-28	IONS	77.29	-203.3	-388.8	-2.56
2026-05-29	IONS	76.50	-203.3	-376.0	-2.56
2026-06-01	IONS	75.37	-100.0	-373.2	-2.56
2026-06-02	IONS	72.99	-100.0	-362.9	-2.56
2026-06-03	IONS	73.79	-100.0	-389.4	-2.56
2026-06-04	IONS	75.12	-100.0	-393.5	-2.56
2026-06-05	IONS	74.45	-100.0	-376.8	-2.56
2026-06-08	IONS	73.57	-100.0	-374.8	-2.56
2026-06-09	IONS	74.55	-100.0	-390.9	-2.56
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-05-11	IONS	-28.66	2.60	8.49
2026-05-12	IONS	-28.66	2.60	10.05
2026-05-13	IONS	-28.66	2.60	10.05
2026-05-14	IONS	-28.66	2.60	10.05
2026-05-15	IONS	-28.66	2.60	10.05
2026-05-18	IONS	-28.73	2.58	10.05
2026-05-19	IONS	-28.62	2.58	10.05
2026-05-20	IONS	-28.62	2.58	10.05
2026-05-21	IONS	-27.93	2.58	10.05
2026-05-22	IONS	-27.93	2.58	10.05
2026-05-26	IONS	-27.93	1.44	10.05
2026-05-27	IONS	-28.24	1.44	10.05
2026-05-28	IONS	-28.24	1.44	9.93
2026-05-29	IONS	-27.77	1.44	9.93
2026-06-02	IONS	-27.77	1.26	9.93
2026-06-03	IONS	-27.77	1.26	9.93
2026-06-04	IONS	-27.45	1.26	9.93
2026-06-05	IONS	-27.45	1.26	9.93
2026-06-08	IONS	-27.45	1.30	9.93
2026-06-09	IONS	-27.45	1.30	9.93
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.3

Avg. EPS Est. Current Quarter

-0.87

Avg. EPS Est. Next Quarter

-0.81

Insider Transactions

-27.45

Institutional Transactions

1.3

Beta

0.38

Average Sales Estimate Current Quarter

189

Average Sales Estimate Next Quarter

203

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-52.4

Target Price

105.23

P/E

Forward P/E

PEG

P/S

11.65

P/B

25.18

P/Free Cash Flow

EPS

-2.1

Average EPS Est. Cur. Y

-2.56

EPS Next Y. (Est.)

-0.62

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-30.87

Relative Volume

0.82

Return on Equity vs Sector %

-94

Return on Equity vs Industry %

-77.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.77

EBIT Estimation

-390.9

◆ IONS Healthcare

$74.58

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

0/20

Pullback

15/25

Volume

7/15

Valuation

7/20

TP/AR

5/10

Options

7/10

RSI

48.5

Range 1M

36.5%

Sup Dist

2.2%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

3/25

Growth

20/30

Estimates

6/20

Inst/Vol

4/15

Options

6/10

EPS Yr

-51.9%

EPS NY

67.7%

52W%

76.6%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +41.1% upside

Quality

6/30

Valuation

10/30

Growth

15/25

Stability

5/10

LT Trend

0/5

Upside

+41.1%

Quality

Ionis Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 1402

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

IONS

Latest News

—

Caricamento notizie per IONS…

stock quote shares IONS – Ionis Pharmaceuticals, Inc. Stock Price stock today

news today IONS – Ionis Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch IONS – Ionis Pharmaceuticals, Inc. yahoo finance google finance

stock history IONS – Ionis Pharmaceuticals, Inc. invest stock market

stock prices IONS premarket after hours

ticker IONS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: IONS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y